Clinical Trial: Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

U.S., July 11 -- ClinicalTrials.gov registry received information related to the study (NCT07694414) titled 'Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events' on July 01.

Brief Summary: The goal of this clinical trial is to investigate the safety of rituximab for management of immune-related adverse events in malignant melanoma patients. The main questions it aims to answer are:

* Is rituximab safe for management of immune-related adverse events in malingnant melanoma patients?

* Does rituximab provide indications of clinical benefit in the management of immune-related adverse events compared with corticosteroid treatment alone?

Participants will:

* Receive a single dose of 100 mg rituximab IV

* Ha...